Orofer (ANTIANEMIC )

Quick links

Choose a section

Quick links to important sections

Advertisements

Orofer (ANTIANEMIC )

Advertisements
Advertisements

Method of action: Antianemic

Advertisements

Overview of Orofer (ANTIANEMIC )

Quick Facts

Property Description
Active ingredient Iron(III)-Hydroxide Polymaltose Complex (IHP) & Folic Acid (Vitamin B9)
Form Oral Tablets, Capsules, Syrup, or Suspension
Pharmacological class Antianemic preparation, Haematinic
Common use Supports blood formation processes (Hematopoiesis)
Origin Synthetic Micronutrient Combination

What Type of Medicine is Orofer and How is it Classified?

Orofer is a pharmaceutical preparation classified as an antianemic agent and haematinic, which means its primary role is to supply the necessary raw materials for the body to correct deficiencies that compromise blood cell production. It is a combination product that falls into the broader category of nutritional supplements targeted toward blood and blood-forming organs. This formulation is designed to provide comprehensive foundational support for hematopoiesis, the vital process of blood renewal. Iron polymaltose is a complex of ferric iron and a polymer of maltose, designed to facilitate iron delivery.

Composition of Orofer: Iron and Folic Acid

The core composition of Orofer comprises two primary active ingredients: Iron(III)-Hydroxide Polymaltose Complex (IHP) and Folic Acid (Pteroylglutamic acid, or Vitamin B9). This pairing addresses the frequent co-occurrence of iron and folate deficiencies. The inclusion of IHP provides a non-salt-based form of iron, belonging to the group of iron trivalent oral preparations. Folic Acid is a crucial water-soluble B vitamin essential for metabolic pathways, including DNA synthesis. The product is intended for the oral route of administration and is manufactured in multiple dosage forms, including tablets, capsules, and syrup or oral suspension, often positioned for use in patient groups such as pregnant women or children due to the availability of liquid formats.

General Purpose: Why is Orofer Used for Hematopoiesis?

The general purpose of this preparation is to ensure the body has the requisite iron and Folic Acid to sustain the continuous and critical differentiation of blood cells. Iron is necessary for the synthesis of hemoglobin, which directly facilitates oxygen transport, while Folic Acid is required for the DNA synthesis that enables the rapid production and maturation of new blood cells. By providing these two essential micronutrients concurrently, the preparation supports erythropoiesis, aiming to help restore the blood's capacity for systemic oxygen delivery. The specific IHP complex is used for patients who may experience gastric discomfort with traditional ferrous salts.

Advertisements

What side effects are possible with Orofer (ANTIANEMIC )?

Orofer, which contains the active ingredient iron sucrose, is an intravenous iron replacement therapy used to treat iron deficiency anemia. Like all medicines administered intravenously, it carries a risk of side effects, including serious hypersensitivity reactions.

Common and Less Common Side Effects

Many side effects associated with iron sucrose are mild and temporary. The most frequently reported adverse reactions affect the gastrointestinal, nervous, and musculoskeletal systems, as well as the injection site. These may include:

  • Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain, or a temporary change in taste (metallic taste).
  • Nervous System: Headache, dizziness, or light-headedness.
  • Musculoskeletal: Muscle cramps, back pain, or pain in the arms/legs or joints (arthralgia).
  • Local: Pain, burning, swelling, or redness at the injection or infusion site. Accidental leakage (extravasation) can lead to brown discoloration of the skin.

Serious Safety Information

Hypersensitivity Reactions: Serious, life-threatening allergic reactions, including anaphylaxis and anaphylactoid reactions, have been reported. For this reason, the administration of iron sucrose requires monitoring by a healthcare professional for at least 30 minutes after the infusion is complete. Symptoms of a severe reaction can include difficulty breathing, hives, itching, swelling of the face, loss of consciousness, or cardiovascular collapse. Seek immediate medical attention if these occur.

Hypotension: Clinically significant low blood pressure (hypotension) may occur, often related to the rate of administration or total dose. Patients are monitored for signs of hypotension during and after administration.

Contraindications: This medication is not recommended for patients with a known hypersensitivity to iron sucrose, any component of the formulation, anemia not caused by iron deficiency, or evidence of iron overload (hemosiderosis).

Monitoring: Regular blood tests, including hemoglobin, hematocrit, and iron indices (serum ferritin and transferrin saturation), are essential to monitor the effectiveness of the treatment and to prevent the risk of iron overload.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information

The official overdose profile for Iron(III)-Hydroxide Polymaltose Complex and Folic Acid is strictly based on the documented risks and regulator-mandated emergency actions.

Feature Official Regulatory Statements
Documented Overdose Presentations Gastrointestinal symptoms (nausea, vomiting, abdominal pain) and lethargy are linked to the iron component. Central nervous system changes, including mood disorders, irritability, and sleep disturbances, are reported with excessive Folic Acid doses.
Physiological Systems Affected Gastrointestinal, cardiovascular (circulatory collapse), central nervous system, hepatic (acute necrosis), and renal systems in severe iron intoxication.
Emergency-Response Statements Contact immediately your doctor, pharmacist, or the poison units in case of overdose. Immediate transfer to hospital is required in cases where intoxication symptoms manifest.
Antidote and Management The specific antidote for severe iron intoxication is deferoxamine. Treatment includes monitoring serum iron levels and provision of supportive and symptomatic measures.
Population-Specific Overdose Notes Iron-based preparations present a documented risk of poisoning, especially in children.

Connection to the overall overdose profile: Official regulatory documentation defines the overdose profile primarily by the potential for acute iron toxicity, which, despite the low toxicity of the complex, includes the documented risk of circulatory collapse and acute organ failure. This risk necessitates a mandated emergency intervention, requiring immediate medical consultation and hospitalization to initiate monitoring, supportive care, and, if needed, the administration of the specific antidote, deferoxamine.

Advertisements

Therapeutic Uses of Orofer (ANTIANEMIC )

What Orofer (ANTIANEMIC) Treats: Main Uses and Benefits

The therapeutic application of Orofer is primarily used to help address and support the management of deficiencies of iron and folic acid, and consequently, managing the symptomatic consequences of a compromised blood system. The primary goal of this category of medicine is to help manage conditions associated with low blood levels of iron (anemia).


Therapeutic Focus and Symptom Relief

This preparation is commonly used to help with addressing manifest iron deficiency anemia (IDA) and folate deficiency anemia. It is also relevant for managing latent iron deficiency, assisting with the replenishment of iron stores before the condition results in noticeable physiological strain. It provides support that helps ease the overall symptom burden by addressing symptom clusters related to systemic imbalance, such as chronic fatigue, general weakness, pallor, and poor concentration. This preparation may be part of symptomatic management in contexts marked by increased physiological stress, notably during pregnancy and lactation.

“This preparation helps patients cope more steadily with symptom fluctuations and supports general well-being.”

It assists with maintaining functional stability for the mother and supports the developing fetus or infant, and is applied in addressing situations where symptoms may intensify temporarily, such as following chronic blood loss.

Quick Fact: Relief for Fatigue
Primary Use: Support for Iron Deficiency Anemia (IDA) and Folate Deficiency (relevant in conditions characterized by periods of heightened symptoms).
Symptom Focus: Chronic fatigue, physical weakness, and poor concentration (symptoms related to systemic imbalance).
Target Contexts: High demand periods (pregnancy, lactation) and nutritional deficit management (applied across domains where additional symptomatic support is needed).

Regulatory References

  1. NIH MedlinePlus overview of Iron
Advertisements

Eligibility and Restrictions for Use

Eligibility and Contraindications for Orofer

The official eligibility profile for Orofer, an antianemic preparation, is defined by strict rules in regulatory documents, identifying specific patient groups who must not use the medicine.

Eligibility Status Population/Condition Regulatory Basis
Contraindicated Known hypersensitivity to the active ingredient(s) or any excipient. Strict exclusion
Contraindicated Evidence of iron overload (e.g., hemochromatosis, hemosiderosis). Risk of iron toxicity
Contraindicated Anemias not caused by iron deficiency. To prevent inappropriate treatment
Contraindicated Disorders of iron utilization (e.g., sideroblastic anemia). To prevent iron accumulation
Not Recommended Children and adolescents aged 12 years and younger (oral/capsule forms). Lack of sufficient data

Use of this medicine is explicitly prohibited for individuals with a history of severe allergic reactions to the preparation, as well as for those diagnosed with iron overload conditions, as the body cannot safely process additional iron. Furthermore, it is contra-indicated for types of anemia that are not caused by a deficit of iron, ensuring that the treatment is only administered when medically appropriate. For the oral formulation, official labeling advises against use in children aged 12 and under, reflecting a lack of established safety and efficacy in this pediatric group.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Orofer is defined by the distinct actions of its two components: the Iron(III)-Hydroxide Polymaltose Complex (IHP) and Folic Acid. The IHP structure is associated with fewer constraints than simple iron salts: regulatory studies document that co-administration with Tetracyclines or Aluminium Hydroxide causes no significant reduction in absorption for either agent, and absorption is not impaired by food constituents. However, administration with Parenteral Iron Preparations is formally not indicated because this combination reduces the absorption of the oral iron component.

Timing separation is required for other agents. Products containing Calcium or Levothyroxine must be separated from Orofer administration by at least two hours to avoid documented reduction in absorption of either medicine.

The Folic Acid component contributes to exposure-modifying patterns. Folic Acid is documented to increase the metabolism of Phenytoin, leading to lower serum Phenytoin concentrations and potential increased seizure risk, a concern noted particularly in folate deficient patients. Folic Acid may also decrease the therapeutic response to Methotrexate, and the resorption of Folic Acid is reduced by Ethanol (Alcohol).

Advertisements

Mechanism of Action

Controlled Regulation of Iron Absorption

Orofer, often formulated as Ferric Hydroxide Polymaltose Complex (IPC), acts by providing a stable, non-ionic form of trivalent iron (Fe^3+). This mechanism bypasses the standard, competitive absorption pathways used by ionic iron salts, enabling a controlled delivery and regulated uptake of iron through mucosal cells. This approach enables a regulated supply of iron to the systemic circulation by reducing the level of non-complexed iron species. The delivery of essential iron contributes to meeting the metabolic demand required for erythropoiesis.

Fueling the Erythropoietic Synthesis Cascade

The essential iron delivered by the drug, along with any included Folic Acid, is immediately channeled to the bone marrow to engage the Erythropoietic Synthesis Pathway. Iron functions as the essential cofactor for the final step of Heme synthesis, and Folic Acid is a necessary substrate for DNA and protein synthesis in developing red blood cell (RBC) precursors. The presence of these substrates facilitates the cell division and maturation phases of erythroid precursors. This process results in the incorporation of iron into Hemoglobin, which establishes the molecule's functional capability for oxygen transport.

Advertisements

Dosage and Administration Information

How to Use Orofer (ANTIANEMIC )

The administration of this combination preparation, containing Iron(III)-Hydroxide Polymaltose Complex (IHP) and Folic Acid, follows standardized instructions focusing solely on the oral route of administration. The preparation is available in multiple forms, including tablets, capsules, and oral solution/syrup, designed to accommodate various patient needs and ages.

Dosing Frequency and Administration Timing

The medicine is typically used on a once-daily regimen, although the total dose may be divided into two smaller doses if prescribed. A key administration constraint is that the medicine must be taken with or immediately after a meal to enhance tolerance and minimize potential gastrointestinal discomfort. Liquid forms, such as the syrup or oral drops, may be mixed with fruit juice or bottle-feed to facilitate intake.

Use Duration and Population-Specific Rules

Treatment duration is structured as a continuous regimen that extends beyond the resolution of clinical symptoms. Standard protocols indicate that use must continue for at least one month and often three to five months following the normalization of blood parameters to ensure the complete repletion of the body's iron stores.

For specific groups, such as pregnant and lactating women, the recognized application acknowledges the increased physiological demand, with Folic Acid components sometimes dosed up to 0.8 mg daily for maintenance. Pediatric use is primarily managed with the liquid forms, with the dose calculated based on the child's body weight or age.

Advertisements

Recent Clinical Evidence

Research Evidence for Orofer (ANTIANEMIC)


Evidence for Use in Correcting Iron Deficiency Anemia (IDA)

Research exploring the use of this preparation to address Iron Deficiency Anemia (IDA) primarily relies on Randomized Controlled Trials (RCTs). These studies examined comparisons of the Iron(III)-Hydroxide Polymaltose Complex (IPC) to other standard oral iron forms, measuring key blood markers like Hemoglobin (Hb) and Serum Ferritin in adults and children. These trials typically covered a short-term period of one to four months.

Findings describe patterns where Hb and Ferritin measurements were often reported to be comparable to those seen with traditional iron salts. However, when research examined these outcomes in groups such as children, the reported findings sometimes varied, showing inconsistency in the rate of change compared directly to standard ferrous salts.


Evidence for Use During Pregnancy

Studies focused on addressing iron and folic acid deficiency during pregnancy, primarily in the second and third trimesters. Research monitored changes in Maternal Hemoglobin and Serum Ferritin. Findings reported similar measurements in maternal blood parameters compared to those receiving other standard iron salts. It remains uncertain how the use of this complex may link to long-term developmental outcomes in the child.


Long-Term Studies and Follow-Up

Most available research focuses on short-term to intermediate-term follow-up, typically lasting up to five months, which is the duration observed in studies that monitor initial changes in anemia status. Long-term effects are not fully established, and there is limited information for assessing the stability of iron levels or the durability of the response over extended periods.


Research Gaps and Uncertainties

A key limitation is the inconsistency of comparative findings, particularly concerning the rate of change in key markers when contrasted with standard ferrous salts in children. Additionally, data for other groups, such as older adults or those with certain chronic conditions, remain insufficient. Evidence quality varies across studies, and research findings describe group patterns, not outcomes for specific individuals.

Key Studies & References

  1. Guideline: Daily oral iron and folic acid supplementation in pregnant women (WHO, informing general context on pregnancy deficiency management)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Orofer (ANTIANEMIC ) (FAQ)


Q: Is Orofer the same as other iron supplements I can buy?

A: Official documents describe this preparation as containing trivalent iron (Fe^3+) in a stable complex, which gives it a structure similar to ferritin, the body's natural iron storage protein. This complex is absorbed via a process different from that used by common ionic iron salts.

Q: How long does it usually take for Orofer to start showing an effect?

A: The folic acid component is documented to be rapidly absorbed. However, the iron component is released and absorbed gradually via a controlled process. Official information indicates that addressing the clinical symptoms of iron deficiency may require continuous use over a period of treatment.

Q: Can Orofer be taken long-term for chronic iron deficiency?

A: According to official product information, this preparation is indicated for both the curative treatment and prevention of iron deficiency. Official use is typically continued for at least one additional month after blood values normalize to ensure the body's iron stores are fully replenished.

Q: Is Orofer known to cause stomach upset more than other iron medicines?

A: The complex structure is intended to reduce the gastrointestinal irritation sometimes associated with other forms of iron. Reported gastrointestinal side effects, such as nausea or diarrhea, are typically described as occasional or rare in official documents.

Q: Does Orofer interact with common pain relievers like paracetamol?

A: Regulatory studies examining the iron component (IPC) have not shown any interaction when it is combined with paracetamol (acetaminophen), which is a common pain reliever.

Q: Is there a specific time of day that is described as best for taking Orofer?

A: Official product information states that the medicine must be taken with or immediately after a meal to help enhance tolerance. Regulatory documents do not mandate a specific time of day, such as morning or evening, for administration.

Q: What happens if I miss a scheduled dose of Orofer?

A: If a dose is missed, the patient information leaflet advises skipping that dose and continuing with the regular dosing schedule. Regulatory documents state that a double dose should not be taken to make up for a forgotten dose.

Q: Is Orofer suitable for children or only adults?

A: According to official product information, this preparation is indicated for use in infants, adolescents, and adults. The liquid forms are available and may be used for younger children, while the oral tablet/capsule forms may not be recommended for children 12 years and under.

Q: Can individuals with kidney conditions typically use Orofer?

A: Official guidance indicates this product is generally contraindicated for individuals with severe kidney diseases.

Q: Does Orofer change the color of stools?

A: The patient information leaflet notes that dark discolouration or blackening of the faeces may occur during treatment with oral iron. This effect is described as normal and harmless.

Q: Why is Orofer sometimes described as 'chelated' or 'ferric' iron?

A: The iron component in this preparation is in the ferric form (Fe^3+). The active ingredient is a complex where the iron is bound to polymaltose molecules, which is a key characteristic of a complexed iron formulation.

Q: Is it necessary to have a blood test before starting treatment with Orofer?

A: Official warnings advise that a deficiency in vitamin B12 must be excluded prior to starting treatment. This is because the Folic Acid component can potentially mask a B12 deficiency.

Q: Can Orofer affect the results of certain laboratory tests?

A: Regulatory documents state that this preparation is documented not to impair the results of the Haemoccult test, which is used to detect occult blood in the stool.

Q: Do official guidelines mention using Orofer to prevent iron deficiency?

A: Official guidelines state that the preparation is explicitly indicated for both the treatment and the prevention of iron and folic acid deficiency.

Q: Why do some people experience constipation when taking iron supplements like Orofer?

A: The complex is intended to reduce the gastrointestinal irritation associated with other forms of iron. Side effects such as constipation, nausea, or diarrhea are generally possible but are reported as occasional or rare.

Q: Does Orofer contain any common allergens like gluten or lactose?

A: The medicine's excipients may include substances such as lactose, sucrose, or sorbitol. Patients with known hypersensitivity to excipients or certain rare hereditary problems, such as fructose intolerance, are advised against taking the medicine.

Q: How quickly is the iron from Orofer absorbed into the body?

A: The iron component is absorbed in the small intestine through an active absorption process. Official documents note that the absorption rate is variable from person to person and depends on the degree of iron deficiency present.

Q: Are there any warnings for people with specific stomach conditions before using Orofer?

A: Official warnings indicate that special caution is required for individuals with an acute gastrointestinal disease. The medicine is also explicitly contraindicated for patients diagnosed with disorders of iron utilization.

Q: How does the iron component of Orofer compare to dietary iron?

A: The polynuclear iron core of the complex has a structure documented to be similar to ferritin, the body’s naturally occurring iron storage protein. Due to this similarity, the iron is absorbed through an active absorption process.

Q: Can Orofer cause or contribute to skin issues?

A: The list of undesirable effects reports that allergic reactions can rarely occur, which may include skin issues such as erythema (redness) and skin rash.

Q: Is it common to feel fatigued during the initial days of taking Orofer?

A: Fatigue is a common symptom of iron deficiency itself. While headache and dizziness are listed as possible side effects, fatigue is not typically listed as a common adverse effect of the medicine itself in regulatory documents.

Q: Does official documentation describe any impact of Orofer on mental clarity or energy?

A: Official reports on high-dose or overdosage of the Folic Acid component have described central nervous system changes, including difficulty in concentrating, altered sleep patterns, and irritability.

Q: Can the effectiveness of Orofer be reduced by drinking coffee or tea?

A: Official regulatory documentation states that because the iron is in a complex form, the ionic interaction with food constituents, which typically reduces the absorption of iron, is not anticipated.

Q: Is Orofer considered a long-term solution or a short-term treatment?

A: Treatment requires a continuous regimen for a period determined by a physician. Official administration information states that treatment must continue for at least one additional month after clinical symptoms resolve to ensure the body's iron stores are fully replenished.

Q: Can Orofer cause temporary darkening of the teeth?

A: Official information indicates that certain dosage forms, such as chewable tablets, are documented not to cause teeth staining. For liquid forms, prevention strategies such as using a straw or mixing with juice have been noted.

Q: Why might a doctor prescribe Orofer over a diet change?

A: The preparation is primarily indicated for the treatment of established iron deficiency and anemia. Official classification highlights that the use of this preparation is for a medical condition that requires therapeutic intervention beyond what can be corrected by dietary management alone.

Q: Is Orofer generally considered safe for people with diabetes?

A: The patient information leaflet advises that caution should be taken if a patient has been diagnosed with diabetes.

Advertisements

How should Orofer (ANTIANEMIC ) be stored and disposed of?

How to Store and Dispose of Orofer

The storage and disposal of Orofer (Iron(III)-Hydroxide Polymaltose Complex and Folic Acid) must adhere strictly to official regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Requirement Specific Condition
Temperature Store below 30 C (controlled room temperature).
Protection Must be kept in a dry place and protected from light.
Container Keep in the original container and ensure the bottle is tightly closed.

Child-Safety and Disposal

Due to the serious risk of accidental iron overdose, this medicine must be kept out of the sight and reach of children. The shelf life is validated only when the product is stored under the specified conditions. Unused or expired Orofer should be disposed of in accordance with local regulations, as regulatory documents do not specify special handling or waste precautions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Orofer (ANTIANEMIC ) found in:

A-Z Index: